Save the Date! 19-21 February 2020 / Grand Hyatt / Washington DC
Membership
ISCTM Meeting Archives
ISCTM Meeting Archives
Videos and Presentations beginning with the 9th Annual Scientific Meeting are public access. Viewing prior materials will require logging into the ISCTM website.
Membership
Join/Renew, update your profile, view membership categories/dues, access member directory, member benefits, Sustaining Corporation members.
Working Groups
Overview of current and completed working groups, links to ISCTM guidance responses, information on joining and/or starting an ISCTM Working Group.
Publications
Search for ISCTM related publications, access ISCTM Innovations in Clinical Neuroscience supplements.
Upcoming Calendar
5-7 September 2019 – Autumn Conference includes Joint meeting with ECNP
Register online through noon CEST, 4 September.
Onsite registration opens, Thursday 5 September, 17:00 – Ballroom 180/181 Lobby
Hotel Bella Sky, Copenhagen, DK
Center Boulevard 5, Copenhagen 2300 Denmark
Mark your calendars
1 November 2019 – New Investigator Award Applications Due
Submission Details
19-21 February 2020 – 16th Annual Meeting
Grand Hyatt, Washington DC
22-23 September – 2020 Autumn Conference
The Boston Park Plaza, Boston, MA
Call for Participation – New ISCTM Working Group Forming
Utilizing Artificial Intelligence and Machine Learning for CNS Clinical Trials
Chairs: Larry Alphs, MD, PhD; Adam Butler
The past 5 years have seen a huge increase in the new applications of both machine learning and artificial intelligence in drug discovery and development. In clinical trials settings, these technologies are being used in a myriad of ways;
- In the development of novel digital endpoints for use in patient trials.
- In precision medicine, supporting the establishment of more exact diagnostic and trial inclusion and exclusion criteria.
- In imaging and biomarkers, increasing sensitivity and augmenting signal detection.
- In drug discovery, automation of drug target identification.
We are convening a Working Group to gather those who are currently utilizing these tools, to engage trialists who would like to utilize these tools, and bring to the table those who are cautious or concerned about these tools, and begin an effort to better understand how they will impact our trials. (Read more)